1	Seroprevalence of measles and varicella in healthcare workers in Chonburi province,
2	Thailand between October 2022 and January 2023
3	
4	Apirat Katanyutanon <sup>1</sup> , Wichai Thanasopon <sup>1</sup> , Chaninan Sonthichai <sup>2</sup> , Piyada
5	Angsuwatcharakorn <sup>2</sup> , Jira Chansaenroj <sup>3</sup> , Ratchathorn Nakabut <sup>4</sup> , Sarandhorn Naritpavalun <sup>4</sup> ,
6	Yanathep Prasitsomsakul <sup>4</sup> , Paranyu Surakhot <sup>4</sup> , Phuvich Pompim <sup>4</sup> , Nasamon Wanlapakorn <sup>3,5</sup> ,
7	Yong Poovorawan <sup>3,6*</sup>
8	
9	<sup>1</sup> Chonburi Provincial Public Health Office, Bansuan, Mueang Chonburi, Chonburi, 20000,
10	Thailand.
11	<sup>2</sup> Vaccine protection, Division of Communicable Diseases, Department of Disease Control,
12	Ministry of Public Health, Nonthaburi, Thailand
13	<sup>3</sup> Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine,
14	Chulalongkorn University, Bangkok 10330, Thailand
15	<sup>4</sup> Secondary school, Triamudomsuksa School, Bangkok, Thailand
16	<sup>5</sup> Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University
17	<sup>6</sup> FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok, 10300, Thailand
18	
19	Running head: Seroprevalence of measles and varicella in healthcare workers
20	*Corresponding author
21	Address for correspondence: Yong Poovorawan, M.D. Center of Excellence in Clinical
22	Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University,
23	Bangkok, Thailand. E-mail: yong.p@chula.ac.th
24	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Katanyutanon A., et al. 2

#### 25 Abstract

- 26 Introduction: Health care workers (HCWs) face the risk of contracting and transmitting
- vaccine-preventable infectious diseases (VPDs). Therefore, it is crucial to evaluate the 27
- 28 immune status of HCWs against certain VPDs, such as measles and varicella zoster virus
- 29 (VZV). This study aimed to determine age-specific seropositivity rates of anti-measles and
- anti-VZV IgG in HCWs working in Chonburi province, Thailand, and to develop a measles 30
- 31 and varicella vaccination policy for Thai HCWs.
- Methods: A total of 266 HCWs in Chonburi Province, Thailand, were enrolled in this study 32
- 33 between October 2022 and January 2023. Participants were divided into six age groups: 21-
- 30, 31-40, 41-50, 51-60, 61-70, and >70 years. Anti-measles and anti-VZV IgG levels were 34
- evaluated using commercial ELISA kits (EUROIMMUN, Lübeck, Germany). 35
- 36 *Results:* The overall seropositivity rates for measles and varicella were 85.0% and 81.2%,
- 37 respectively. The lowest seropositivity rates for both measles and varicella were found among
- the 21-30-year-old group. Furthermore, seropositivity rates increased with age, reaching 38
- 39 100% among people over the age of 60 years.
- 40 Conclusions: To prevent measles and VZV outbreaks in HCWs, it is crucial to implement
- catch-up measles and varicella vaccination programs, particularly among HCWs younger 41
- 42 than 30 years of age.
- 43 Keywords: Seroprevalence, Measles, Varicella, Healthcare workers
- 44
- 45 46
- 47
- 48
- 49

Katanyutanon A., et al. 3

### 50 Introduction

51 Measles and varicella zoster virus (VZV) are extremely contagious diseases that manifest with skin eruptions. The secondary attack rate of measles and varicella ranges 52 53 between 70% and 90% among susceptible exposed individuals [1]. The basic reproduction number of measles and varicella ranges from 13 to 18 and 3.7 to 5.0, respectively [2, 3]. The 54 measles vaccine was developed in the 1970s and was integrated into the Expanded 55 56 Programme on Immunization (EPI) worldwide in 1974 [4]. The live attenuated varicella vaccine, derived from the VZV Oka strain, has been licensed for more than a decade [5, 6]. 57 58 Despite the decline in the incidence of measles and varicella resulting from widespread 59 vaccination efforts, outbreaks of these two diseases have been reported in settings where children gather, such as childcare centers and schools, in hospitals, institutionalized children 60 61 and adults' facilities, refugee camps, and among healthcare workers (HCWs) [7-10]. 62 HCWs are at increased risk for measles than the general population. In the United States, 78 documented cases of measles were attributed to transmission within healthcare 63 64 facilities [11]. Furthermore, 29 healthcare personnel contracted the virus through occupational exposure, with one individual transmitting the measles virus to a patient. 65 Consequently, the CDC's Advisory Committee on Immunization Practices (ACIP) 66 recommends that HCWs who were born before 1957 or who lack serological evidence of 67 immunity or prior vaccination should receive a two-dose regimen of the measles-mumps-68 69 rubella (MMR) vaccine, with a minimum interval of four weeks between doses [12]. 70 The VZV vaccine, also known as chickenpox vaccine, is a live-attenuated vaccine for protection against chickenpox (varicella) [7, 13]. The currently licensed varicella vaccines are 71 72 highly effective in preventing varicella and its complications [14, 13]. However, varicella outbreaks have been reported, including among healthcare workers in Thailand [15]. Previous 73 seroprevalence studies showed high levels of seronegativity among healthcare workers 74

75 ranging from 14–15.6% in Malaysia and Saudi Arabia, to as high as 51% among first-year 76 medical and engineering students in Sri Lanka [16-18]. In Thailand, the varicella vaccine is 77 an optional vaccine. Thus, the coverage is low. A previous study of VZV seroprevalence in 78 Thailand conducted among university students found that 26% were seronegative to anti-79 VZV antibodies, suggesting that one in four young Thai adults remained susceptible to 80 varicella [19]. The CDC's ACIP recommends that for varicella, HCWs born after 1970, 81 without a history of varicella and/or a negative result on the antibody screening test, are advised to receive a two-dose vaccination series. 82 83 To develop a measles and varicella vaccination policy for Thai HCWs, it is important to understand the seroprevalence of these two diseases. Currently, there are neither 84 serological screening nor a catch-up vaccination campaign in the HCWs working in Chonburi 85 86 Province, Thailand. This study aimed to investigate the immune status of HCWs against 87 measles and varicella in a variety of healthcare settings located in Chonburi province, 88 Thailand and to define an appropriate vaccination program among HCWs. 89

#### Methods 90

#### 91 Study design and ethical considerations

92 This cross-sectional study was part of the large-scale serosurvey conducted in 11 districts in Chonburi province, Thailand, between October 2022 and January 2023 [20]. In 93 94 the large-scale serosurvey, there was a total of 1193 general population and 266 HCWs. The cluster random sampling method was used to enroll participants. The stratified clusters within 95 96 the 11 districts were divided into urban and rural strata. From each district, each cluster was 97 selected using the probability proportionate-to-size sampling method. Healthcare workers 98 were selected from distinct-level health facilities within each district using consecutive

Katanyutanon A., et al. 5

99 sampling in each district. In the present study, only serological samples from 266 HCWs 100 were analyzed.

101 The protocol received approval from the Institutional Review Board of the Faculty of 102 Medicine of Chulalongkorn University (IRB numbers 0706/65). This study adhered to the 103 ethical principles stated in the Declaration of Helsinki and followed the principles of good 104 clinical practice. Prior to their participation in the study, written consent was obtained from 105 each participant.

106

107 Participants and Sample Collection

108 HCWs were approached for eligibility. Exclusion criteria included aged <18 years or > 80 years, having immunosuppressive disorders, malignancy, or diseases that require 109 110 immunosuppressive agents. A structured questionnaire was applied to voluntary HCWs. The 111 data collected in this study included age, sex, history of measles and varicella infection, and 112 previous vaccination.

113 Blood samples of 3-5 milliliters (mL) were collected and subsequently subjected to 114 centrifugation to obtain serum samples, which were aliquoted and stored at -20°C until further 115 laboratory tests.

116

117 Laboratory testing

118 Seroprevalence of Measles and VZV

119 Commercial enzyme-linked immunosorbent assay (ELISA) kits were used according 120 to the manufacturer's instructions to measure IgG concentrations against measles and VZV 121 (EURROIMMUN, Lubeck, Germany). Serum samples were initially diluted 1:100 and then 122 further diluted to obtain values within the detection range. Anti-measles and anti-VZV IgG

Katanyutanon A., et al. 6

123	concentrations are expressed in international units per liter (IU/L). The cut-off for
124	seropositivity and seroprotection rate against measles in this study was $\geq$ 275 IU/L. The cut-
125	off for seropositivity and seroprotection rate against varicella in this study was $\geq$ 110 IU/L.
126 127	Statistical Analysis
128	Data on the seropositivity rates of anti-measles IgG and anti-VZV IgG are presented
129	as numbers and percentages. Geometric mean titers (GMT) were calculated. The associations
130	between sex and GMT were performed using Person's chi-square test. Comparison of
131	logarithmic-transformed GMTs between groups was compared using one-way ANOVA. All
132	statistical analyses were performed with SPSS v23.0 (IBM Corp., Chicago, IL). Figures were
133	generated using GraphPad Prism v9.4.1 (GraphPad Software, San Diego, CA). A p-
134	value $< 0.05$ was considered statistically significant.
135	
136	Results
137	Demographic characteristics of study participants
138	In this study, a total of 266 HCWs were included for the seroprevalence studies of
139	measles and varicella. The mean age was 38.3 years (Table 1). There were more female than
140	male participants in this study (77.8% female versus 22.2% male). Most of the HCWs were
141	between 21-30 years old, followed by 31-40 years and 41-50 years old. Only 5.6% of the
142	HCWs (15/266) indicated that they had contracted measles, while 21.8% (58/266) reported
143	having been vaccinated against measles. On the contrary, up to 48.1% (128/266) indicated
144	that they had contracted varicella, while only 4.9% (13/266) reported having been vaccinated
145	against varicella.

Seroprotection rates and GMTs against measles and VZV in healthcare workers

146

Katanyutanon A., et al. 7

147	Table 2 shows the proportion of HCWs who achieved seroprotection rates against
148	measles and their GMTs by age groups. Overall, 85% of the HCWs in this study had an anti-
149	measles IgG of $> 275$ IU/L with a GMT of 1128.0 (964.5 – 1320.0) IU/L. A high
150	seroprotection rate (>98%) was observed in older individuals 41 years of age. The lowest
151	seroprotection rate was found among HCWs in the age group of 21–30 years (68.2%).
152	HCWs in the 41-50- and 51-60-year-old age groups had significantly higher anti-measles IgG
153	GMTs than the 21-30-old age group as shown in Table 2 ( $p$ -value < 0.001). There were no
154	significant differences in GMT between male and female HCWs ( $p$ -value = 0.457).
155	Table 3 shows the proportion of HCWs who achieved the seroprotection rate against
156	varicella and their GMTs by age groups. A total of 81.2% (216/266) of HCWs achieved a
157	seroprotection rate against varicella, with a GMT of 394.0 (315.4-492.0) IU/L. Similar to
158	measles, a high seroprotection rate (>90%) was observed in older individuals from 41 years
159	of age. The lowest seroprotection rate for varicella was also found among HCWs in the 21-
160	30-year-old age group (64.8%). HCWs in the 41-50- and 51-60-year-old age groups had
161	significantly higher anti-VZV IgG GMTs than the 21-30-old age group as shown in Table 3
162	( <i>p</i> -value $< 0.05$ ). No significant differences in the seroprotection rate were found between
163	male and female HCWs ( $p$ -value = 0.508). In particular, the seroprotection rate against
164	measles and VZV gradually increased with age and reached 100% in HCWs over 60 years of
165	age.
166	Correlation between serological results and self-reported medical history.
167	Table 4 shows the correlation between the seroprotection rates against measles and
168	VZV and the history of previous vaccination and infection. HCWs with a self-reported

170 in 86.7-89.7% of cases, but not significantly higher than in those who did not report previous

history of previous measles infection or vaccination had protective levels of anti-measles IgG

169

infection or vaccination. On the contrary, a history of previous varicella was more frequent 171

172	among those who were immune to varicella ( $p$ -value = 0.018) than among those who were
173	susceptible. HCWs who reported having no previous vaccination against varicella were more
174	likely to be immune ( <i>p</i> -value $< 0.001$ ), suggesting that the positive serological results were
175	due to natural infection. The positive predictive value of the history of varicella was 89.84%,
176	where it was 86.67% for the history of measles (Table 5). The positive predictive value of the
177	history of varicella vaccination was 76.92%, where it was 89.66% for the history of measles
178	vaccination. The negative predictive value of the was low for both measles and varicella
179	infection and vaccination in this study.

180

#### Discussion 181

Vaccination for HCWs is an essential step in protecting not only HCWs but also 182 183 patients and communities [21, 22]. To establish an effective immunization program, a 184 serological survey is necessary to obtain the immune status of HCWs, together with a history of previous infection and vaccination, are necessary. Our study showed high seroprotection 185 186 rates of more than >90% for measles (anti-measles IgG > 275 IU/L) and VZV (anti-VZV IgG 187 > 110 IU/L) in HCWs older than 41 years working in Chonburi Province, Thailand, even 188 when the policy for the screening and vaccination campaign in HCWs has not been 189 implemented. This preexisting immunity is likely to result from natural exposure before the 190 EPI for measles and varicella vaccinations were in place for all infants. On the contrary, 191 individuals between 21-30 years of age who were born under the universal measles 192 vaccination for all infants at 9 months of age had the lowest seroprotection rate for measles. 193 A recent seroprevalence survey in Thai adolescents also showed that, despite 70% 194 documented one- or two-dose measles vaccination during childhood, only half of the 195 adolescents had anti-measles IgG greater than 275 IU/L, likely due to the decline of 196 antibodies without natural exposure or primary vaccine failure [23]. Thus, in this study,

Katanyutanon A., et al. 9

197 HCWs younger than 30 years of age who could have been vaccinated against measles under 198 the EPI program could possibly have anti-measles immunity that waned overtime. 199 Furthermore, the second dose of measles-containing vaccine coverage among Thai children 200 reached more than 80% of the population only after 2016, suggesting that a large number of 201 populations may have received only one dose of measles-containing vaccine during 202 childhood [24]. Thus, it is important to prioritize a catch-up campaign for measles 203 vaccination for young healthcare workers who had no history of two-dose measles 204 immunization or had negative serology.

205 In the present study, the overall seroprotection rate for measles in HCWs was lower 206 than in the general population over 26 years of age in our previous serosurvey conducted in 207 2014 (85% versus 97.7%) [25]. The younger generation of the 2030s, having been born under 208 the Expanded Program on Immunization (EPI) with improved vaccine coverage, may possess 209 vaccine-induced immunity that diminishes over time, resulting in lower seroprevalence rates 210 during adulthood compared to the previous survey 10 years ago. Additionally, comparison of 211 anti-measles seroprevalence among HCWs from different regions showed that HCWs from 212 high-income countries had a higher rate of measles seroprevalence ranging from 87% to 97% 213 than HCWs in our study [9].

214 Our study showed that the overall seroprotection rate against varicella was 81.2% 215 This rate was lower compared to HCWs in Japan (96.3%) [26], Finland (99%) [27], Denmark 216 (98.6%) [28], and Korea (91%) [29, 30]. In Thailand, older individuals acquired immunity to 217 varicella through natural exposure, while younger individuals may have received varicella 218 vaccination, which are optional vaccines, or may have contracted the disease during 219 childhood. Therefore, younger HCWs are likely to have a low seroprotection rate compared 220 to older HCWs due to the low coverage of optional vaccines and the lack of exposure to natural infection. Other countries also reported low anti-VZV seroprevalence rates in the 221

Katanyutanon A., et al. 10

young population [31]. Based on our results, it is recommended to prioritize varicella
vaccination for HCWs in the 21-30 age group with negative serology and no record of twodose varicella vaccination.

225 The correlation between self-reported history and seroprotected status showed that 226 neither history of measles vaccination nor history of measles were associated with 227 seroprotected status. Our results are consistent with other studies showing that self-reported 228 vaccination history may not be predictive and reliable [27]. Therefore, when a measles 229 vaccination record was not available, serologic tests should be performed to provide evidence 230 of measles immunity. Unlike measles, we found that a history of previous varicella was more 231 frequent among those who were immune to varicella. This is similar to the report of a Thai 232 university student showing the significant association between the history of varicella and the 233 seropositivity rate [19]. Consistent with a previous report, negative predictive values for both 234 previous vaccination and infection were very low for both measles and varicella [30]. Our 235 research indicates the necessity of implementing a universal record system to document 236 vaccine administration for every individual in Thailand. The universal record system could 237 potentially reduce unnecessary serologic screening and catch-up vaccinations.

This study has some limitations. First, the participants' history of vaccination and previous infection was only obtained through questionnaires, which resulted in missing information and uncertain information regarding diagnosis, actual vaccination doses, and dates. Selecting HCWs from one province may not fully represent all HCWs in Thailand. A larger study that explores other regions of Thailand could provide a more comprehensive representation of the entire country. Additionally, the small sample size of participants older than 60 years makes it challenging to draw conclusive results.

245

246 Conclusions

247	This study provides comprehensive information to inform policy makers and establish
248	effective measles and varicella immunization programs for HCWs throughout the country. To
249	prevent measles and VZV outbreaks in HCWs, it is crucial to conduct serological screening
250	and implement catch-up measles and varicella vaccination programs, particularly among
251	HCWs younger than 30 years of age.
252	
253	Acknowledgements
254	We greatly appreciate the kind contributions and collaboration of all participants. With all of
255	their help, the interesting information obtained from this study could be used for the future
256	development of vaccine strategies. We thank all staff from the hospitals in Chonburi Province
257	for enrolling participants and staff from the Center of Excellence in Clinical Virology,
258	Faculty of Medicine, Chulalongkorn University, for their help with the laboratory testing.
259	
260	Ethics approval
261	The study protocol was reviewed and approved by the Institutional Review Board (IRB),
262	Faculty of Medicine, Chulalongkorn University (IRB 0706/65). Written informed consent
263	was waived by the IRB.
264	
265	Conflict of interest statement
266	The authors have no conflict of interest to declare.
267	
268	Funding
269	This research was financially supported by the Health Systems Research Institute (HSRI), the
270	National Research Council of Thailand (NRCT), the Research Chair Grant from the National
271	Science and Technology Development Agency (P-15-50004), the Center of Excellence in

272	Clinic	cal Virology, Chulalongkorn University, and King Chulalongkorn Memorial Hospital
273	and th	ne Second Century Fund (C2F) of Jira Chansaenroj, Chulalongkorn University. The
274	funde	rs had no role in study design, data collection, analysis, publication decision, or
275	manu	script preparation.
276		
277	Auth	or contributions
278	Conce	eptualization: Y.P.; Data curation: A.K., W.T., J.C., N.W.; Formal analysis: A.K., J.C.,
279	N.W.	; Funding acquisition: J.C., Y.P.; Investigation: A.K., W.T.; Methodology: A.K., J.C.;
280	Proje	ct administration: J.C., R.N., S.N., Y.P., P.S., P.P.; Resources: A.K., W.T., C.S., P.A.;
281	Softw	vare: J.C., N.W.; Supervision: Y.P.; Validation: A.K., N.W., Y.P.; Visualization: J.C.;
282	Roles	/Writing - original draft: A.K., J.C., R.N., S.N., Y.P., P.S., P.P., N.W. ;and Writing –
283	review	w & editing: A.K., N.W.
284		
285	Data	availability statement
286	The a	uthors confirm that all data supporting the findings of this study are available within the
287	article	2.
288		
289	Refer	rences
290		
291	[1]	Lee JS, Jeong O, Yang H. Screening and Vaccination Against Measles and Varicella
292		Among Health Care Workers: A Cost-effectiveness Analysis. Asia Pac J Public
293		Health. 2021 Jul;33(5):508-515. doi: 10.1177/10105395211026468. Epub 2021 Jun
294		24. PMID: 34165349.
295	[2]	Guerra FM, Bolotin S, Lim G, Heffernan J, Deeks SL, Li Y, et al. The basic
296		reproduction number $(R(0))$ of measles: a systematic review. Lancet Infect Dis. 2017

Katanyutanon A., et al. 13

- 297 Dec;17(12):e420-e428. doi: 10.1016/S1473-3099(17)30307-9. Epub 2017 Jul 27.
- **298** PMID: 28757186.
- 299 [3] Marangi L, Mirinaviciute G, Flem E, Scalia Tomba G, Guzzetta G, Freiesleben de
- 300 Blasio B, et al. The natural history of varicella zoster virus infection in Norway:
- 301 Further insights on exogenous boosting and progressive immunity to herpes zoster.
- 302 PLoS One. 2017;12(5):e0176845. doi: 10.1371/journal.pone.0176845. PMID:
- **303** 28545047; PMCID: PMC5436649.
- 304 [4] Okwo-Bele JM, Cherian T. The expanded programme on immunization: a lasting
- 305 legacy of smallpox eradication. Vaccine. 2011 Dec 30;29 Suppl 4:D74-79. doi:
- 306 10.1016/j.vaccine.2012.01.080. PMID: 22486980.
- 307 [5] Hinman A. Eradication of vaccine-preventable diseases. Annu Rev Public Health.
- 308 1999;20:211-229. doi: 10.1146/annurev.publhealth.20.1.211. PMID: 10352857.
- 309[6]Arvin AM, Greenberg HB. New viral vaccines. Virology. 2006 Jan 5;344(1):240-249.

doi: 10.1016/j.virol.2005.09.057. PMID: 16364754.

- 311 [7] Gershon AA. Viral vaccines of the future. Pediatr Clin North Am. 1990
- 312 Jun;37(3):689-707. doi: 10.1016/s0031-3955(16)36911-5. PMID: 2161508.
- 313 [8] Baxter R, Ray P, Tran TN, Black S, Shinefield HR, Coplan PM, et al. Long-term
- 314 effectiveness of varicella vaccine: a 14-Year, prospective cohort study. Pediatrics.
- 315 2013 May;131(5):e1389-96. doi: 10.1542/peds.2012-3303. Epub 2013 Apr 1. PMID:
  316 23545380.
- 317 [9] Haviari S, Benet T, Saadatian-Elahi M, Andre P, Loulergue P, Vanhems P.
- 318 Vaccination of healthcare workers: A review. Hum Vaccin Immunother.
- 319 2015;11(11):2522-2537. doi: 10.1080/21645515.2015.1082014. PMID: 26291642;
- 320 PMCID: PMC4685699.

- 321 [10] Minta AA, Ferrari M, Antoni S, Portnoy A, Sbarra A, Lambert B, et al. Progress
- 322 Toward Regional Measles Elimination Worldwide, 2000-2021. MMWR Morb
- 323 Mortal Wkly Rep. 2022 Nov 25;71(47):1489-1495. doi: 10.15585/mmwr.mm7147a1.
- 324 PMID: 36417303; PMCID: PMC9707362.
- 325 [11] Fiebelkorn AP, Redd SB, Kuhar DT. Measles in Healthcare Facilities in the United
- 326 States During the Postelimination Era, 2001-2014. Clin Infect Dis. 2015 Aug
- 327 15;61(4):615-618. doi: 10.1093/cid/civ387. Epub 2015 May 15. PMID: 25979309;
- 328 PMCID: PMC4646220.
- 329 [12] Advisory Committee on Immunization P, Centers for Disease C, Prevention.
- 330 Immunization of health-care personnel: recommendations of the Advisory Committee
- on Immunization Practices (ACIP). MMWR Recomm Rep. 2011 Nov 25;60(RR-7):1-
- **332 45.** PMID: 22108587.
- 333 [13] Weinmann S, Naleway AL, Koppolu P, Baxter R, Belongia EA, Hambidge SJ, et al.
- Incidence of Herpes Zoster Among Children: 2003-2014. Pediatrics. 2019 Jul;144(1).
- doi: 10.1542/peds.2018-2917. Epub 2019 Jun 10. PMID: 31182552; PMCID:
- **336** PMC7748320.
- 337 [14] Salvetti A, Ferrari V, Garofalo R, Gazzaniga P, Guerroni A, Metrucci A, et al.
- 338 Incidence of herpes zoster and postherpetic neuralgia in Italian adults aged
- 339 >/=50 years: A prospective study. Prev Med Rep. 2019 Jun;14:100882. doi:
- 340 10.1016/j.pmedr.2019.100882. PMID: 31193254; PMCID: PMC6522697.
- 341 [15] Apisarnthanarak A, Kitphati R, Tawatsupha P, Thongphubeth K, Apisarnthanarak P,
- 342 Mundy LM. Outbreak of varicella-zoster virus infection among Thai healthcare
- 343 workers. Infect Control Hosp Epidemiol. 2007 Apr;28(4):430-434. doi:
- 344 10.1086/512639. Epub 2007 Feb 26. PMID: 17385149.

Katanyutanon A., et al. 15

345	[16]	Almuneef MA,	Memish ZA, Ball	chy HH, Otaibi I	B, Helmi M. Sero	prevalence survey	y
-----	------	--------------	-----------------	------------------	------------------	-------------------	---

- of varicella, measles, rubella, and hepatitis A and B viruses in a multinational
- 347 healthcare workforce in Saudi Arabia. Infect Control Hosp Epidemiol. 2006
- 348 Nov;27(11):1178-1183. doi: 10.1086/508826. Epub 2006 Oct 17. PMID: 17080374.
- 349 [17] Sam IC, Tariman H, Chan YF, Bador MK, Yusof MY, Hassan H. Varicella-zoster
- 350 virus seroprevalence in healthcare workers in Kuala Lumpur, Malaysia. Med J

351 Malaysia. 2008 Dec;63(5):429-430. PMID: 19803311.

- 352 [18] Kurukulasooriya GM, Thevanesam V, Agampodi SB, Abeykoon AM, Amarasiri SP,
- 353 Goonasekera KP. Susceptibility of New Entrant University students in Sri Lanka to
- varicella zoster infection. Asia Pac J Public Health. 2010 Apr;22(2):219-224. doi:

355 10.1177/1010539509334625. Epub 2009 May 1. PMID: 19411280.

- 356 [19] Bhattarakosol P, Chantarabul S, Pittayathikhun K, Mung-mee V, Punnarugsa V.
- 357 Prevalence of anti-varicella zoster IgG antibody in undergraduate students. Asian Pac

358 J Allergy Immunol. 1996 Dec;14(2):129-31. PMID: 9177828.

- 359 [20] Chansaenroj J, Suntronwong N, Kanokudom S, Assawakosri S, Vichaiwattana P,
- 360 Klinfueng S, et al. Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-
- 361 RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October
- 362 2022 to January 2023. Sci Rep. 2023 Sep 20;13(1):15595. doi: 10.1038/s41598-023-
- 363 42754-2. PMID: 37730917; PMCID: PMC10511501.
- 364 [21] Paterson P, Meurice F, Stanberry LR, Glismann S, Rosenthal SL, Larson HJ. Vaccine
- hesitancy and healthcare providers. Vaccine. 2016 Dec 20;34(52):6700-06. doi:
- 366 10.1016/j.vaccine.2016.10.042. Epub 2016 Oct 31. PMID: 27810314.
- 367 [22] Gaviola GC, McCarville M, Shendale S, Goodman T, Lomazzi M, Desai S. A review
- 368 of health worker vaccination programs in low, middle and upper middle-income

369		countries. Public Health Pract (Oxf). 2023 Dec;6:100415. doi:
370		10.1016/j.puhip.2023.100415. PMID: 37547811; PMCID: PMC10400463.
371	[23]	Puthanakit T, Anugulruengkitt S, Angsuwatcharakon P, Bunjoungmanee P,
372		Kowitdamrong E, Primsirikunawut A, et al. Low Measles Seropositivity Rate among
373		Thai Adolescents in the Thai National Immunization Program. Vaccines (Basel). 2022
374		Aug 6;10(8). doi: 10.3390/vaccines10081269. PMID: 36016157; PMCID:
375		PMC9412740.
376	[24]	Measles vaccination coverage. World Health Organization: World Health
377		Organization; 2023. Available from:
378		https://immunizationdata.who.int/pages/coverage/mcv.html?CODE=SEAR&ANTIGE
379		N=MCV2&YEAR=
380	[25]	Wanlapakorn N, Wasitthankasem R, Vichaiwattana P, Auphimai C, Yoocharoen P,
381		Vongpunsawad S, et al. Antibodies against measles and rubella virus among different
382		age groups in Thailand: A population-based serological survey. PLoS One.
383		2019;14(11):e0225606. doi: 10.1371/journal.pone.0225606. PMID: 31770412;
384		PMCID: PMC6879141.
385	[26]	Kumakura S, Shibata H, Onoda K, Nishimura N, Matsuda C, Hirose M.
386		Seroprevalence survey on measles, mumps, rubella and varicella antibodies in
387		healthcare workers in Japan: sex, age, occupational-related differences and vaccine
388		efficacy. Epidemiol Infect. 2014 Jan;142(1):12-9. doi: 10.1017/S0950268813000393.
389		Epub 2013 Apr 11. PMID: 23574767; PMCID: PMC3857110.
390	[27]	Koivisto K, Puhakka L, Lappalainen M, Blomqvist S, Saxen H, Nieminen T.
391		Immunity against vaccine-preventable diseases in Finnish pediatric healthcare
392		workers in 2015. Vaccine. 2017 Mar 14;35(12):1608-14. doi:
393		10.1016/j.vaccine.2017.02.018. Epub 2017 Feb 21. PMID: 28233625.

204	<b>FOO1</b>	T ' A N/T	VI. NI. I	17:1-1 NT		NT	W. alter T	D1 1.
394	28	von Linstow ML.	Y de Nielsen A.	, KIIKDY IN,	, Eltveat A,	Nordmann	winther I	, Bydeck

- 395 Nielsen A, et al. Immunity to vaccine-preventable diseases among paediatric
- healthcare workers in Denmark, 2019. Euro Surveill. 2021 Apr;26(17). doi:
- 397 10.2807/1560-7917.ES.2021.26.17.2001167. PMID: 33928900; PMCID:
- **398** PMC8086246.
- 399 [29] Yun JH, Lee E, Choi JH, Ki HK, Park J. Seroprevalence of Varicella-Zoster Virus
- 400 and Measles among Healthcare Workers in a Tertiary Medical Center in Korea.
- 401 Vaccines (Basel). 2022 Nov 18;10(11). doi: 10.3390/vaccines10111956. PMID:
- 402 36423051; PMCID: PMC9697537.
- 403 [30] Shin L, Choi JR, Huh K, Chung DR, Cho SY, Jeong J, et al. Trend of immunity
- 404 against measles and varicella zoster virus in healthcare workers in Korea. Vaccine.
- 405 2023 Jul 19;41(32):4679-84. doi: 10.1016/j.vaccine.2023.06.018. Epub 2023 Jun 20.
- 406 PMID: 37349224.
- 407 [31] Yoo Y, Park WJ, Cho S, Lim DY, Kim S, Kang W, et al. Seroprevalence of measles,
  408 mumps, rubella, and varicella-zoster antibodies in new female nurses in the Republic
- 409 of Korea. Ann Occup Environ Med. 2021;33:e19. doi: 10.35371/aoem.2021.33.e19.
- 410 PMID: 34754480; PMCID: PMC8264122.
- 411
- 412
- 413
- 414
- 415
- 416
- 417
- 418

Katanyutanon A., et al. 18

## Table 1. Demographic characteristics of the HCWs included in this study (N=266) 419

Mean age, years (SD)	38.3 (11.5)
Sex	N (%)
Male	59 (22.2)
Female	207 (77.8)
Past history of measles	N (%)
Yes	15 (5.6)
No	230 (86.5)
Jncertain	21 (7.9)
Previous vaccination against measles	N (%)
/es	58 (21.8)
lo	75 (28.2)
Jncertain	133 (50.0)
ast history of varicella	N (%)
les	128 (48.1)
lo	122 (45.9)
Jncertain	16 (6.0)
Previous varicella vaccination	N (%)
les	13 (4.9)
lo	149 (56.0)
Jncertain	104 (39.1)

420 421

Table 2. Seroprevalence of anti-measles IgG in HCWs by age group and sex. 423

424

Variables	No.	Proportion of seroprotected individuals, N (%)	GMT (IU/L) (95% CI)	<i>p</i> -value (One-way ANOVA)
All	266	226 (85.0)	1128.0 (964.5 - 1320.0)	
Age groups (years)				
21-30	88	60 (68.2)	614.8 (454.5 - 831.7)	Reference
31-40	75	65 (86.7)	1036.5 (783.1 – 1372.0)	0.030
41-50	54	53 (98.1)	2095.8 (1584.0 - 2773.0)	< 0.0001*
51-60	43	42 (97.7)	1969.9 (1512.0 – 2567.0)	< 0.0001*
61-70	4	4 (100)	2135.1 (319.1 – 14285.0)	0.193
>70	2	2 (100)	1037.4 (2.1 – 522915.0)	0.976
Sex		. ,	· · · · · · · · · · · · · · · · · · ·	
Male	59	52 (88.1)	1261 (935.7 – 1699.0)	0.457
Female	207	174 (84.1)	1093 (909.7 - 1313.0)	

425

GMT: Geometric mean titer, \* = statistically significant

<sup>422</sup> 

426

### 427 Table 3. Seroprevalence of anti-VZV IgG in HCWs by age group and sex

# 428

Variables	No.	Proportion of seroprotected individuals, N (%)	GMT (IU/L) (95% CI)	<i>p</i> -value (One-way ANOVA)
All	266	216 (81.2)	394.0 (315.4 - 492.0)	
Age				
groups				
(years)				
21-30	88	57 (64.8)	239.6 (148.6 - 386.2)	Reference
31-40	75	63 (84.0)	326.7 (213.8 - 499.1)	0.774
41-50	54	50 (92.6)	617.7 (436.3 - 874.4)	0.012*
51-60	43	40 (93.0)	791.4 (553.3 – 1132.0)	0.002*
61-70	4	4 (100)	767.1 (127.8 - 4605.0)	0.659
>70	2	2 (100)	616.3 (33.1 – 11461.0)	0.947
Sex			· · · · · · · · · · · · · · · · · · ·	
Male	59	50 (84.7)	453.3 (268.2 - 766.0)	0.508
Female	207	166 (80.2)	378.5 (296.1 - 483.9)	

<sup>429</sup> GMT: Geometric mean titer, \* = statistically significant

Table 4. The Correlation between the serological results of anti-measles anti-VZV IgG with 431 the self-reported medical history. 432

433

Variables	Total (N=266)	Immune (seroprotected) N (%)	Nonimmune (susceptible) N (%)	<i>p</i> -value
Measles				
History of vaccination				0.064
Yes	58	52 (89.7)	6 (10.3)	
No	75	67 (89.3)	8 (10.7)	
Uncertain or N/A	133	107 (80.5)	26 (19.5)	
History of measles		· · ·		0.864
Yes	15	13 (86.7)	2 (13.3)	
No	230	195 (84.8)	35 (15.2)	
Uncertain or N/A	21	18 (85.7)	3 (14.3)	
Varicella				
History of vaccination				< 0.001*
Yes	13	10 (76.9)	3 (23.1)	
No	149	132 (88.6)	17 (11.4)	
Uncertain or N/A	104	74 (71.2)	30 (28.8)	
History of varicella				0.018*
<b>Yes</b>	128	115 (89.8)	13 (10.2)	
No	122	89 (73.0)	33 (27.0)	
Uncertain or N/A	16	12 (75.0)	4 (25.0)	

434 N/A: Data not available.

<sup>430</sup> 

Katanyutanon A., et al. 20

# 435

- Table 5. Positive predictive values and negative predictive values of the self-reported history 436
- of infection or vaccination. 437
- 438

		Positive predictive value (%)	Negative predictive value (%)
Measles	History of measles	86.67	15.22
	History of vaccination	89.66	10.67
Varicella	History of varicella	89.84	27.05
	History of vaccination	76.92	11.41

439

440